科研之友
微信
新浪微博
Facebook
分享链接
摘要
<jats:title>Abstract</jats:title><jats:p>The serotonin 2C (5‐HT<jats:sub>2C</jats:sub>) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia. In this Viewpoint article, recent progress in developing selective 5‐HT<jats:sub>2C</jats:sub> agonists for use in treating these disorders is summarized, including the work of our group. Challenges in this field and the possible future directions are described. Homology modeling as a method to predict the binding modes of 5‐HT<jats:sub>2C</jats:sub> ligands to the receptor is also discussed. Compared to known ligands, the improved pharmacological profiles of the 2‐phenylcyclopropylmethylamine‐based 5‐HT<jats:sub>2C</jats:sub> agonists make them preferred candidates for further studies.</jats:p>
- 出版日期2015-12
